- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05472467
Camrelizumab Combination With SBRT and Concurrent Chemotherapy Treated Stage IV Oligometastatic Non-small Cell Lung Cancer (IMCORT-2)
Camrelizumab Combination With SBRT and Concurrent Chemotherapy Treated Stage IV Oligometastatic Non-small Cell Lung Cancer ,a Single-arm, Single-center, Exploratory Clinical Study(IMCORT-2)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study evaluated the effectiveness and safety of Camrelizumab combination with SBRT and concurrent chemotherapy treated stage IV oligometastatic non-small cell lung cancer.
The primary endpoint is ORR. Secondary points contains:PFS、OS、DCR、Qol.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: jiahua lyu, doctor
- Phone Number: 17713539529
- Email: winlttljh@163.com
Study Locations
-
-
Sichuan
-
Chengdu, Sichuan, China, 610041
- Recruiting
- Sichuan Cancer Hospital & Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
patients voluntarily enrolled in this study and signed the informed consent form (ICF).
Good compliance and cooperation with follow-up.
- age: 18 to 75 years, both sexes.
- ECOG PS: 0 to 1 score.
- patients with non-small cell lung cancer clearly diagnosed by pathology, with measurable tumor lesions (oligometastases ≥10 mm in length, meeting mRECIST1.1 criteria).
- subjects with clinical stage IV according to the 8th edition of the Clinical Oncology TNM staging Stage IV (≤5 oligometastases, ≤3 metastatic organs, and measurable metastases) non-small cell lung cancer patients according to the 8th edition of TNM staging.
5. patients with stage IV clinical stage (number of oligometastases ≤ 5, metastatic organs ≤ 3, and measurable metastases) non-small cell lung cancer 6. vital organ function meets the following requirements (no blood components and cell growth are allowed 2 weeks prior to the start of study treatment) (No blood components or cell growth factors are allowed 2 weeks prior to the start of study treatment).
(1) Routine blood tests must meet the following requirements.
absolute neutrophil count (ANC) ≥ 1.5 x 109
- L.
- Hemoglobin (HB) ≥ 9 g/dL.
- Platelets (PLT) ≥ 100×109 /L.
- serum albumin (ALB) ≥ 2.8g/dL. (2) Biochemical examination shall comply with.
a) total bilirubin (TBIL) ≤ 1.5 ULN. b) ALT, AST ≤ 2.5 UILN (if liver function abnormalities due to liver metastases, then ≤ 5 ULN) b) ALT, AST ≤ 2.5 UILN (≤ 5 ULN if liver function abnormalities are due to liver metastasis).
c) serum creatinine sCr ≤ 1.5 ULN, endogenous creatinine clearance c) serum creatinine sCr ≤ 1.5 ULN and endogenous creatinine clearance ≥ 50 ml/min (Cockcroft-Gault formula).
7. expected survival ≥ 3 months. 8. the patient is judged by the investigator to be amenable to treatment with kallikreinumab 9. the patient has no autoimmune disease. 10. the patient has not received prior treatment with PD-1/PD-L1 inhibitors. 11. tissue or plasma genetic testing for common lung cancer driver genes such as EGFR, ALK, ROS, RET, HER2, MET, BRAF negative, or no accessible targeted drugs or who are intolerant to targeted drug therapy.
12. Female subjects of childbearing potential should receive their first study drug administration within 12. Female subjects of childbearing potential should have a urine or serum pregnancy test within 72 hours prior to the first study drug administration and demonstrate 12. Female subjects of childbearing potential should have a negative urine or serum pregnancy test within 72 hours prior to the first dose of study drug and be willing to use validated methods during the trial until 3 months after the last administration of cariolizumab. Male subjects whose partners are women of childbearing potential should use an effective method of contraception for the duration of the trial and for 3 months after the last administration of cariolizumab. Male subjects whose partners are women of childbearing potential should use an effective method of contraception during the trial and for 3 months after the last administration of carreliximab
Exclusion Criteria:
- patients who do not meet the inclusion criteria for type of pathology and site of primary focus.
- with diffuse brain metastases and meningeal metastases
have any active autoimmune disease or a history of autoimmune disease such as inter stromal pneumonia, uveitis, enterocolitis, hepatitis, pituitary inflammation, vasculitis myocarditis, nephritis, hyperthyroidism, hypothyroidism (can be included after normal hormone replacement therapy).
may be included after normalization of hormone replacement therapy).
- patients with asthma requiring medical intervention with bronchodilators
- patients with uncontrolled cardiac clinical symptoms or disease, such as. (1) NYHA class II or higher heart failure. (2) Unstable angina pectoris. (3) Myocardial infarction within 1 year. (4) Clinically significant supraventricular or ventricular arrhythmias requiring clinical (4) patients with clinically significant supraventricular or ventricular arrhythmias requiring clinical intervention.
- active infection or unexplained fever of >38.5°C (0.5 mg/kg) during screening or before the first dose Fever >38.5°C (in the judgment of the investigator, subjects with fever due to tumor fever can be enrolled).
- a known history or evidence of interstitial lung disease or active non-infectious pneumonia
- have a congenital or acquired immune deficiency (e.g., HIV-infected), active Hepatitis B (HBV-DNA ≥ 104 copies/mL) or Hepatitis C (Hepatitis C antibody positive and HCV-RNA above the lower limit of detection for the assay).
- prior treatment with other PD-1 monoclonal antibodies or other immunotherapy against PD-1/PDL1
- known hypersensitivity to macromolecular protein agents, or to any of the components of kareolizumab sensitization.
- Requirement for corticosteroids (>10 mg/day, prednisone) within 14 days prior to first administration of study drug.
10 mg/day, prednisone efficacy dose) or other immunosuppressive agents for systemic therapy within 14 days prior to the first Subjects on systemic therapy with corticosteroids (> 10 mg/day, prednisone efficacy dose) or other immunosuppressive agents within 14 days prior to first study drug administration. In the absence of active autoimmune disease In the absence of active autoimmune disease, inhaled or topical steroids and adrenaline at doses >10 mg/day, prednisone efficacy dose are allowed.
Adrenocorticosteroid replacement at efficacious doses of prednisone. 12. have received an antitumor monoclonal antibody (mAb) within 4 weeks prior to the first administration of study drug (mAb) within 4 weeks prior to the first administration of study drug, or adverse events from previously received drugs have not Recovery (i.e., ≤ grade 1 or at baseline level). Note: Occurrence of ≤ grade 2 neuropathy or ≤ grade 2 alopecia.
Note: Subjects with ≤ grade 2 neuropathy or ≤ grade 2 alopecia are excluded if the subject has undergone major surgery.
If the subject has undergone major surgery, the toxic effects and/or complications of the surgical intervention must be adequately addressed prior to initiation of treatment.
Subjects who have undergone major surgery must have recovered sufficiently from the toxic effects and/or complications of their surgical intervention prior to initiation of treatment.
13. the subject is participating in another clinical study 14. the subject has received a live vaccine within 4 weeks prior to the first administration of the study drug and is allowed to receive injectable 14. Receipt of inactivated viral vaccine for seasonal influenza, by injection, but not receive live attenuated influenza vaccine administered via intranasal route. 15. subjects who, in the judgment of the investigator, have other factors that may force them to terminate the other factors that, in the judgment of the investigator, may force him or her to terminate the study, such as other serious illnesses (including mental illness) requiring comorbid treatment, severely abnormal laboratory test values, family or social factors that circumstances that may affect the safety of the subject or the collection of trial data.
16. other circumstances that, in the judgment of the investigator, make inclusion in this study inappropriate
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Immunotherapy combined with Stereotactic Body Radiation Therapy
|
200mg IV Q3W.
Every three weeks is a cycle
stereotactic body radiation therapy for Oligometastases 35Gy/5f(7.0Gy/f,5f
per week)
Other Names:
Squamous carcinoma: docetaxel 60 mg/m2, d1 + cisplatin 25 mg/m2, d1-3 or carboplatin AUC=4-6 d1, 21 days for one cycle, up to 4 cycles. Non-squamous carcinoma: pemetrexed 500 mg/m2, d1 + cisplatin 25 mg/m2, d1-3 or carboplatin AUC=4-6, d1,21 days for one cycle, up to 4 cycles. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
ORR
Time Frame: up to 3 years
|
Objective response rate, according to RECISTv1.1, the proportion of patients with CR or PR was determined.
If the patient has not undergone a post-baseline assessment, it is considered unremission.
|
up to 3 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PFS
Time Frame: up to 3 years
|
progression-free survival (PFS) refers to the time from enrollment to the first recording of disease progression as determined by RECISTv1.1,
or to death due to any cause (whichever occurs first).
PFS will be analyzed in the ITT analysis set.
|
up to 3 years
|
OS
Time Frame: up to 3 years
|
Overall survival (OS) refers to the time from enrollment to the first recorded death due to any cause (whichever occurs first).
|
up to 3 years
|
HRQoL
Time Frame: up to 3 years
|
HRQoL uses EORTCQLQ-C30 to assess the overall health of patients.
The post-baseline score of the treatment group was studied, and the score changes from the baseline were summarized descriptively.
|
up to 3 years
|
HRQoL
Time Frame: up to 3 years
|
HRQoL uses EORTCQLQ-OES18 to assess the overall health of patients.
The post-baseline score of the treatment group was studied, and the score changes from the baseline were summarized descriptively.
|
up to 3 years
|
Collaborators and Investigators
Investigators
- Study Chair: Tao Li, doctor, Sichuan Cancer Hospital and Research Institute
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SCCHEC-01-2021-091
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non-small Cell Lung Cancer Metastatic
-
WindMIL TherapeuticsBristol-Myers SquibbTerminatedNSCLC | Lung Cancer | Lung Cancer Metastatic | Lung Cancer, Non-small Cell | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non Small Cell Lung Cancer MetastaticUnited States
-
Western Regional Medical CenterTerminatedNon-squamous Cell Non-Metastatic Non-Small Cell Lung Cancer | Squamous Cell Non-Metastatic Non-Small Cell Lung CancerUnited States
-
ElephasBeaufort CRORecruitingNSCLC | Non Small Cell Lung Cancer | Metastatic Non Small Cell Lung Cancer | Metastatic NSCLC - Non-Small Cell Lung CancerUnited States
-
AIO-Studien-gGmbHBristol-Myers Squibb; Eli Lilly and Company; Merck Sharp & Dohme LLC; Pfizer; Gilead... and other collaboratorsRecruitingSmall-cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Stage I | Metastatic Non-small Cell Lung Cancer (NSCLC) | Non Small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer Stage IIGermany
-
Genentech, Inc.CompletedNon-Small Cell Lung Cancer, Metastatic Colorectal Cancer, Metastatic Non Small Cell Lung Cancer, Metastatic Cancers, MelanomaUnited States
-
Shandong Boan Biotechnology Co., LtdCompletedMetastatic Colorectal Cancer | Non Small Cell Lung Cancer Metastatic | Non Small Cell Lung Cancer RecurrentChina
-
Incyte CorporationZai Lab (Shanghai) Co., Ltd.Active, not recruitingMetastatic Squamous Non-Small Cell Lung Cancer | Metastatic Nonsquamous Non-Small Cell Lung CancerChina, Czechia, Russian Federation, Serbia, Malaysia, Vietnam, United States, Poland, Ukraine, Romania, Turkey, Brazil, Bulgaria, Georgia, Hungary, Philippines, South Africa
-
TheRas, IncRecruitingNSCLC | Metastatic Lung Cancer | Non-small Cell Lung Cancer | Advanced Lung Carcinoma | Metastatic Non-Small Cell Lung Cancer | KRAS G12CUnited States, Australia
-
Tesaro, Inc.Active, not recruitingNeoplasms | Solid Tumor | Non Small Cell Lung Cancer | Metastatic Cancer | Advanced Cancer | Non Small Cell Lung Cancer Stage IIIB | Non Small Cell Lung Cancer MetastaticUnited States
-
University Hospital Southampton NHS Foundation...Royal Bournemouth and Christchurch Hospitals NHS Foundation TrustUnknownNon Small Cell Lung Cancer | Non Small Cell Lung Cancer Stage IIIB | Non Small Cell Lung Cancer MetastaticUnited Kingdom
Clinical Trials on Camrelizumab
-
Shandong Provincial HospitalUnknown
-
Zhejiang Cancer HospitalUnknown
-
Zhejiang Cancer HospitalNot yet recruitingUterine Cervical Neoplasms | Oncolytic Virotherapy | CamrelizumabChina
-
Peking UniversityNot yet recruiting
-
Hebei Medical University Fourth HospitalRecruiting
-
Nanfang Hospital of Southern Medical UniversityRecruitingNasopharyngeal Carcinoma | Oligometastasis | RadiotherapyChina
-
Fudan UniversityRecruiting
-
Fujian Medical University Union HospitalRecruitingRadiotherapy | Immunotherapy | Esophageal NeoplasmChina
-
Cancer Institute and Hospital, Chinese Academy...Not yet recruiting
-
Henan Provincial People's HospitalNot yet recruiting